论文部分内容阅读
目的:评价普萘洛尔治疗婴幼儿血管瘤的临床疗效。方法:2010年3月—2012年9月,采用口服普萘洛尔治疗53例血管瘤患儿,从0.5mg/(kg·d)开始,逐渐加大剂量至2mg/(kg·d),连续服用,总疗程为2.75~5.75个月。随访7个月,观察并记录血管瘤的颜色、大小,患儿的不良反应,有无反弹。采用SPSS17.0软件包对数据进行统计学分析。结果:治疗2d后,100%的血管瘤颜色变淡;治疗2周后,25.9%的血管瘤直径缩小75%。疗效评价Ⅰ级(差)3例,Ⅱ级(中)18例,Ⅲ级(好)19例,Ⅳ级(优)13例。不同年龄、部位、类型的血管瘤疗效相比无显著差异(P<0.05)。结论:口服普萘洛尔治疗婴幼儿血管瘤安全有效。
Objective: To evaluate the clinical efficacy of propranolol in the treatment of infantile hemangiomas. Methods: From March 2010 to September 2012, 53 children with hemangiomas were treated with propranolol orally. The dose was gradually increased to 2mg / (kg · d) from 0.5mg / (kg · d) Continuous use, the total course of 2.75 ~ 5.75 months. Follow-up for 7 months, observe and record the color, size of hemangiomas, children’s adverse reactions, with or without rebound. SPSS17.0 software package for statistical analysis of the data. RESULTS: After 2 days of treatment, 100% of the hemangiomas became pale in color; after 2 weeks of treatment, 25.9% of the hemangiomas were reduced in diameter by 75%. Efficacy evaluation Ⅰ grade (poor) in 3 cases, Ⅱ grade (middle) in 18 cases, Ⅲ grade (good) in 19 cases, Ⅳ grade (excellent) in 13 cases. There was no significant difference in the efficacy of hemangiomas of different age, location and type (P <0.05). Conclusion: Propranolol is safe and effective for the treatment of infantile hemangiomas.